Business Context and Reporting Period
Company: Prana Biotechnology Limited (ASX: PBT)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2018 (Specifically November 16, 2018)
Context: The filing discloses the issuance of unlisted options to a director and provides an update on the company's capital structure and placement capacity under ASX Listing Rules. The filing incorporates an Appendix 3B regarding a new issue announcement and application for quotation.
Key Financial Metrics and Capital Structure
Revenue, Profit, and Cash Flow: The filing text does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. This document is a regulatory disclosure regarding securities issuance, not a financial results report.
Capital Structure (as of November 16, 2018):
- Fully Paid Ordinary Shares: 536,975,050
- Unlisted Options Issued (Current Transaction): 1,250,000 (Code: PBTAAA)
- Unlisted Options Lapsed: 1,066,490 total across four classes (PBTAY, PBTAZ, PBTAD, PBTAA)
- Total Unlisted Options Outstanding: 26,600,000 (including various classes with exercise prices ranging from AUD$0.07 to AUD$1.12)
Material Changes Versus Prior Period
Securities Issuance: On November 16, 2018, the company issued 1,250,000 unlisted options (PBTAAA) to a director. This issuance was approved by shareholders on November 17, 2017.
Terms of New Issue:
- Exercise Price: AUD$0.11
- Expiry Date: December 14, 2022
- Consideration: Nil cash consideration
- Ranking: Upon exercise, these options convert to Ordinary Shares that rank equally with existing quoted securities.
Administrative Correction: The filing notes a correction to an administrative error in a previously lodged Appendix 3B regarding the total number of PBTAAA options (adjusted to 13,850,000).
Guidance, Outlook, and Regulatory Compliance
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary regarding business operations or financial performance.
Regulatory Compliance (ASX Rules):
- Rule 7.1A Approval: The entity confirmed it is an eligible entity that obtained security holder approval under Rule 7.1A on November 16, 2018.
- Placement Capacity:
- Rule 7.1 Capacity: 80,546,258 shares remaining (15% of base capital).
- Rule 7.1A Capacity: 53,697,505 shares remaining (10% of base capital).
Risks and Contingencies: No specific risks or contingencies are detailed in this filing beyond standard regulatory warranties regarding the legality of the issue.
Important Facts for Investor Verification
- Verify the total number of outstanding options (26.6 million) and their respective exercise prices to assess potential dilution.
- Confirm the exercise price of the newly issued options (AUD$0.11) against the current market price of Prana Biotechnology shares.
- Note that the issuance was for nil cash consideration as part of a director incentive plan approved in 2017.
- Review the company's remaining placement capacity (approx. 80.5 million under Rule 7.1 and 53.7 million under Rule 7.1A) to understand future fundraising flexibility.
- Check for subsequent filings regarding the actual exercise of these options or further capital raises, as this filing contains no financial performance data.